Hanmi Pharm signs modified agreement of long-acting antidiabetic with Sanofi
Hanmi Pharm(CEO Kwan-Soon Lee) announced on the 29th that it signed a partial modification of the license agreement made on November 2015 for ‘Quantum Project,’ a long-acting antidiabetic portfolio, with Sanofi.
According to the modified agreement, development milestones for one of the 3 drug ca...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
